Rituximab-immunoconjugate kit-formulations for NHL radioimmunotherapy

Radioimmunotherapy (RIT) of Non-Hodgkin’s lymphoma (NHL) is said to be more advantageous compared to unlabeled therapeutic antibodies. To this date, radiolabelled murine anti-CD20 mAbs, Zevalin® and Bexxar® have been approved for imaging and therapy. A preparation containing rituximab, chimeric mAb immunoconjugate suitable for Lu-177 labeling, could provide better imaging and therapeutic profile at the same time. This study was conducted to evaluate prepared lyophilized formulations of three rituximab immunoconjugates, intended for immediate Lu-177 labeling, for imaging and therapy. The results showed preserved antibody structure and suitability for successful radiolabeling with over 95% radiochemical purity, encouraging further evaluation experiments